OSE Immunotherapeutics

143 articles with OSE Immunotherapeutics

• OSE Immunotherapeutics Receives a Grant From French Government Program "Fonds Unique Interministériel" to Explore New Cytotoxic Antibodies

  12/15/2017

  This collaborative program is focused on developing innovative tests to explore and to measure the cytotoxicity of monoclonal antibodies.

• OSE Immunotherapeutics to Resume Accrual in Phase III Clinical Trial of Tedopi in Advanced Non-Small Cell Lung Cancer Patients Following Immune Checkpoint Inhibitor Treatment

  12/7/2017

  There continue to be no safety concerns, as safety data remain similar to what was expected for Tedopi® based on the results of previous clinical trials.

• OSE Immunotherapeutics Publishes New Data on FR104, CD28-Antagonist Immunotherapy

  10/19/2017

  FR104 shows immune tolerance superiority over CTLA4-Ig in humanized skin transplant model.

• Selexis SA And OSE Immunotherapeutics Expand Strategic Alliance To Further Advance OSE’s OSE-172 And OSE-703 Cancer Immunotherapy Programs

  9/26/2017

• OSE Immunotherapeutics Announces Temporary Pause Of Patient Accrual While Continuing Treatment For Patients Already Enrolled In Phase III Clinical Trial Of Tedopi In Advanced Lung Cancer

  6/26/2017

• OSE Immunotherapeutics Presents Positive Preclinical Results And Human Ex Vivo Data For OSE-127 (Effi-7) To Support Next Clinical Applications In Inflammatory Bowel Diseases At The Federation Of Clinical Immunology Societies (FOCIS) Conference

  6/15/2017

• OSE Immunotherapeutics Announces Results Of 2017 Annual Meeting Of Shareholders

  6/14/2017

• OSE Immunotherapeutics Announces Strategic Multi-Year Research Collaboration With Memorial Sloan-Kettering Cancer Center In New York

  6/12/2017

• Selexis SA And OSE Immunotherapeutics Sign Commercial License Agreement To Further Advance Development Of OSE's Interleukin Receptor 7 Antagonist

  5/23/2017

• OSE Immunotherapeutics To Present At Annual Sachs Immuno-Oncology: BD&L And Investment Forum

  5/18/2017

• OSE Immunotherapeutics Presents New Data On Anti-SIRPa (Effi-DEM), The Checkpoint Inhibitor Blocking Pro-Tumor And Suppressor Myeloid Cells At “Advances In Immuno-Oncology Congress,” London, May 15-16, 2017

  5/15/2017

• OSE Immunotherapeutics Presented New Data At AACR Annual Meeting 2017 On OSE-172 (Effi-DEM), Company's Checkpoint Inhibitor Blocking Suppressive Myeloid Cells And Inducing Antitumoral Potent T Memory Response

  4/5/2017

• OSE Immunotherapeutics Release: 2016 Results: Significant Milestones, First Profit, More Growth To Come

  3/28/2017

• OSE Immunotherapeutics New Immune Checkpoint Inhibitor OSE-172 (Effi-DEM) At The 24th Molecular Med TRI-CON 2017 Meeting Session "Cancer Immunotherapy"

  2/21/2017

• OSE Immunotherapeutics To Present Corporate Overview At Upcoming BIO CEO & Investor Conference New York February 13-14, 2017

  2/7/2017

• OSE Immunotherapeutics Release: Company Announces That The Independent Data Monitoring Committee (IDMC) Recommends Continuation Of Pivotal Phase 3 Clinical Trial Of Tedopi In Non-Small Cell Lung Cancer

  1/24/2017

• OSE Immunotherapeutics Inks Key Agreement With Paris-Based Servier for Effi-7; OSE to Receive Up to €272 Million and Upfront €10.25 Million

  12/28/2016

• OSE Immunotherapeutics Announces The Online Publication Of Positive Phase I Clinical Results With FR104 In The Journal Of Immunology

  11/17/2016

• Selexis SA And OSE Immunotherapeutics Collaborate To Advance Development Of Immunotherapies For Cancer And Autoimmune Diseases

  11/16/2016

• Selexis SA And OSE Immunotherapeutics Collaborate To Advance Development Of Immunotherapies For Cancer And Autoimmune Diseases

  11/15/2016